ZVSA vs. PCSA, GNPX, THAR, LIPO, KTRA, ARTL, BPTS, VRPX, CING, and ENSC
Should you be buying ZyVersa Therapeutics stock or one of its competitors? The main competitors of ZyVersa Therapeutics include Processa Pharmaceuticals (PCSA), Genprex (GNPX), Tharimmune (THAR), Lipella Pharmaceuticals (LIPO), Kintara Therapeutics (KTRA), Artelo Biosciences (ARTL), Biophytis (BPTS), Virpax Pharmaceuticals (VRPX), Cingulate (CING), and Ensysce Biosciences (ENSC). These companies are all part of the "pharmaceutical preparations" industry.
ZyVersa Therapeutics (NASDAQ:ZVSA) and Processa Pharmaceuticals (NASDAQ:PCSA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.
Processa Pharmaceuticals' return on equity of -141.42% beat ZyVersa Therapeutics' return on equity.
3.9% of ZyVersa Therapeutics shares are owned by institutional investors. Comparatively, 91.9% of Processa Pharmaceuticals shares are owned by institutional investors. 0.7% of ZyVersa Therapeutics shares are owned by insiders. Comparatively, 22.2% of Processa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Processa Pharmaceuticals had 1 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 4 mentions for Processa Pharmaceuticals and 3 mentions for ZyVersa Therapeutics. Processa Pharmaceuticals' average media sentiment score of 0.00 beat ZyVersa Therapeutics' score of -0.33 indicating that Processa Pharmaceuticals is being referred to more favorably in the news media.
Processa Pharmaceuticals received 6 more outperform votes than ZyVersa Therapeutics when rated by MarketBeat users. However, 100.00% of users gave ZyVersa Therapeutics an outperform vote while only 47.37% of users gave Processa Pharmaceuticals an outperform vote.
ZyVersa Therapeutics presently has a consensus price target of $120.00, indicating a potential upside of 2,304.81%. Processa Pharmaceuticals has a consensus price target of $8.00, indicating a potential upside of 272.09%. Given ZyVersa Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe ZyVersa Therapeutics is more favorable than Processa Pharmaceuticals.
ZyVersa Therapeutics has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Comparatively, Processa Pharmaceuticals has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.
Summary
Processa Pharmaceuticals beats ZyVersa Therapeutics on 9 of the 13 factors compared between the two stocks.
Get ZyVersa Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZVSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ZyVersa Therapeutics Competitors List
Related Companies and Tools
